English

Nascent Biotech Inc.

EDGAR

Quarterly report (10-Q) · filed 2024-08-14

52 filing records in this dataset, filed from 2015-02-13 to 2024-08-14. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2023 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-387 thousand USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -1787228 USD Source
Operating Cash Flow: -1400650 USD Source

Cash and cash equivalents: 146 thousand USD 2022-06-30 Source
Exact value

145575 USD
Long-term debt including current maturities: Not available
Shares outstanding: 172 million shares 2024-06-30 Source
Exact value

172202165 shares

Reported share-count change

19.89% · 28.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

143636778 shares · 2023-06-30· Source
172202165 shares · 2024-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-1.92 million USD

2023-07-01 – 2024-06-30

Exact inputs and evidence

Net income: -829476 USD · 2023-07-01 – 2023-09-30 Source
Net income: -205406 USD · 2023-10-01 – 2023-12-31 Source
Net income: -2087682 USD · 2023-04-01 – 2024-03-31 Source
Net income: -1575106 USD · 2023-04-01 – 2023-12-31 Source
Net income: -377390 USD · 2024-04-01 – 2024-06-30 Source

Operating cash flow

-1.35 million USD

2023-07-01 – 2024-06-30

Exact inputs and evidence

Operating cash flow: -504218 USD · 2023-04-01 – 2023-09-30 Source
Operating cash flow: -162706 USD · 2023-04-01 – 2023-06-30 Source
Operating cash flow: -834332 USD · 2023-04-01 – 2023-12-31 Source
Operating cash flow: -504218 USD · 2023-04-01 – 2023-09-30 Source
Operating cash flow: -1186066 USD · 2023-04-01 – 2024-03-31 Source
Operating cash flow: -834332 USD · 2023-04-01 – 2023-12-31 Source
Operating cash flow: -324729 USD · 2024-04-01 – 2024-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-08-14.

Financial data available through: 2023-03-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2023-03-31
Operating income: 10 of 11 periods available· newest 2023-03-31
Net income: 10 of 11 periods available· newest 2023-03-31
Operating cash flow: 10 of 11 periods available· newest 2023-03-31
capital expenditure: No compatible figures in this window
Total assets: 6 of 11 periods available· newest 2023-03-31
Total liabilities: 6 of 11 periods available· newest 2023-03-31
Current assets: 6 of 11 periods available· newest 2023-03-31
Current liabilities: 6 of 11 periods available· newest 2023-03-31
Cash and cash equivalents: 5 of 11 periods available· newest 2022-03-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2023-03-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 1 million

2021-04-01 – 2022-03-31
Current period

USD 0

2022-04-01 – 2023-03-31

Exact inputs and evidence

0 − 1000000 = -1000000 USD

1000000 USD · 2021-04-01 – 2022-03-31
Inspect prior input Prior source
0 USD · 2022-04-01 – 2023-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Nascent Biotech Inc. · 2023-03-31 Nascent Biotech Inc. (edgar:1622057) Year-over-year change in Revenue: -1000000 USD Concept: fundies:Revenue Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793224001231/nbio_s1.htm#797352 Filing: 000147793224001231 Input fundies:Revenue: 1000000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793224001231/nbio_s1.htm#797906 Filing: 000147793224001231
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 2.33 million

Prior period

−USD 470,390

2021-04-01 – 2022-03-31
Current period

−USD 2.8 million

2022-04-01 – 2023-03-31

Exact inputs and evidence

-2800969 − -470390 = -2330579 USD

-470390 USD · 2021-04-01 – 2022-03-31
Inspect prior input Prior source
-2800969 USD · 2022-04-01 – 2023-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Nascent Biotech Inc. · 2023-03-31 Nascent Biotech Inc. (edgar:1622057) Year-over-year change in Net income: -2330579 USD Concept: fundies:NetIncome Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -2800969 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793224004020/nbio_10k.htm#540905 Filing: 000147793224004020 Input fundies:NetIncome: -470390 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793224001231/nbio_s1.htm#943460 Filing: 000147793224001231
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-532.2%

Prior period

USD 413,479

2021-04-01 – 2022-03-31
Current period

−USD 1.79 million

2022-04-01 – 2023-03-31

Exact inputs and evidence

-1787228 − 413479 = -2200707 USD

413479 USD · 2021-04-01 – 2022-03-31
Inspect prior input Prior source
-1787228 USD · 2022-04-01 – 2023-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Nascent Biotech Inc. · 2023-03-31 Nascent Biotech Inc. (edgar:1622057) Year-over-year change in Operating cash flow: -2200707 USD Concept: fundies:OperatingCashFlow Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -1787228 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793224004020/nbio_10k.htm#609453 Filing: 000147793224004020 Input fundies:OperatingCashFlow: 413479 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793224001231/nbio_s1.htm#963161 Filing: 000147793224001231
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2022-04-01 – 2023-03-31

Revenue USD 0
Operating costs Derived USD 2.16 million
Operating income −USD 2.16 million
Tax, interest and other Derived USD 645,212
Net income −USD 2.8 million

Cash

Operating cash flow −USD 1.79 million
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 38%9.7%52%
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 287% of revenue.
2022 Operating loss: operating costs were 146% of revenue.
2023 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2016-04-01 – 2017-03-31	3000000	1572578 Derived	1427422	290485 Derived	1136937	Unavailable	Source 2016-04-01 – 2017-03-31: 3000000 USD Inspect Revenue Open source 2016-04-01 – 2017-03-31: 1427422 USD Inspect Operating Income Open source 2016-04-01 – 2017-03-31: 1136937 USD Inspect Net Income Open source 2016-04-01 – 2017-03-31: -768844 USD Inspect Operating Cash Flow Open source
2019 2018-04-01 – 2019-03-31	0	1368948 Derived	-1368948	-41 Derived	-1368907	Unavailable	Source 2018-04-01 – 2019-03-31: 0 USD Inspect Revenue Open source 2018-04-01 – 2019-03-31: -1368948 USD Inspect Operating Income Open source 2018-04-01 – 2019-03-31: -1368907 USD Inspect Net Income Open source 2018-04-01 – 2019-03-31: -711808 USD Inspect Operating Cash Flow Open source
2020 2019-04-01 – 2020-03-31	0	3447311 Derived	-3447311	556842 Derived	-4004153	Unavailable	Source 2019-04-01 – 2020-03-31: 0 USD Inspect Revenue Open source 2019-04-01 – 2020-03-31: -3447311 USD Inspect Operating Income Open source 2019-04-01 – 2020-03-31: -4004153 USD Inspect Net Income Open source 2019-04-01 – 2020-03-31: -554325 USD Inspect Operating Cash Flow Open source
2021 2020-04-01 – 2021-03-31	750000	2150368 Derived	-1400368	-441601 Derived	-958767	Unavailable	Source 2020-04-01 – 2021-03-31: 750000 USD Inspect Revenue Open source 2020-04-01 – 2021-03-31: -1400368 USD Inspect Operating Income Open source 2020-04-01 – 2021-03-31: -958767 USD Inspect Net Income Open source 2020-04-01 – 2021-03-31: -986783 USD Inspect Operating Cash Flow Open source
2022 2021-04-01 – 2022-03-31	1000000	1457052 Derived	-457052	13338 Derived	-470390	Unavailable	Source 2021-04-01 – 2022-03-31: 1000000 USD Inspect Revenue Open source 2021-04-01 – 2022-03-31: -457052 USD Inspect Operating Income Open source 2021-04-01 – 2022-03-31: -470390 USD Inspect Net Income Open source 2021-04-01 – 2022-03-31: 413479 USD Inspect Operating Cash Flow Open source
2023 2022-04-01 – 2023-03-31	0	2155757 Derived	-2155757	645212 Derived	-2800969	Unavailable	Source 2022-04-01 – 2023-03-31: 0 USD Inspect Revenue Open source 2022-04-01 – 2023-03-31: -2155757 USD Inspect Operating Income Open source 2022-04-01 – 2023-03-31: -2800969 USD Inspect Net Income Open source 2022-04-01 – 2023-03-31: -1787228 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-03-31	Revenue	3000000	Revenue: 3000000 Open source
20192019-03-31	Revenue	0	Revenue: 0 Open source
20202020-03-31	Revenue	0	Revenue: 0 Open source
20212021-03-31	Revenue	750000	Revenue: 750000 Open source
20222022-03-31	Revenue	1000000	Revenue: 1000000 Open source
20232023-03-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Year over year	No prior comparable period	Revenue: 3000000 Open source
20192019-03-31	Year over year	No prior comparable period	Revenue: 0 Open source
20202020-03-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20212021-03-31	Year over year	No prior comparable period	Revenue: 750000 Open source Revenue: 0 Open source
20222022-03-31	Year over year	33.3%	Revenue: 1000000 Open source Revenue: 750000 Open source
20232023-03-31	Year over year	-100%	Revenue: 0 Open source Revenue: 1000000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -45.7% 2022

Net margin -47% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Operating margin	47.6%	Operating Income: 1427422 Open source Revenue: 3000000 Open source
20192019-03-31	Operating margin	Not reported	Operating Income: -1368948 Open source Revenue: 0 Open source
20202020-03-31	Operating margin	Not reported	Operating Income: -3447311 Open source Revenue: 0 Open source
20212021-03-31	Operating margin	-186.7%	Operating Income: -1400368 Open source Revenue: 750000 Open source
20222022-03-31	Operating margin	-45.7%	Operating Income: -457052 Open source Revenue: 1000000 Open source
20232023-03-31	Operating margin	Not reported	Operating Income: -2155757 Open source Revenue: 0 Open source
20172017-03-31	Net margin	37.9%	Net Income: 1136937 Open source Revenue: 3000000 Open source
20192019-03-31	Net margin	Not reported	Net Income: -1368907 Open source Revenue: 0 Open source
20202020-03-31	Net margin	Not reported	Net Income: -4004153 Open source Revenue: 0 Open source
20212021-03-31	Net margin	-127.8%	Net Income: -958767 Open source Revenue: 750000 Open source
20222022-03-31	Net margin	-47%	Net Income: -470390 Open source Revenue: 1000000 Open source
20232023-03-31	Net margin	Not reported	Net Income: -2800969 Open source Revenue: 0 Open source
20172017-03-31	Free cash flow margin	Not reported	Revenue: 3000000 Open source Operating Cash Flow: -768844 Open source
20192019-03-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -711808 Open source
20202020-03-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -554325 Open source
20212021-03-31	Free cash flow margin	Not reported	Revenue: 750000 Open source Operating Cash Flow: -986783 Open source
20222022-03-31	Free cash flow margin	Not reported	Revenue: 1000000 Open source Operating Cash Flow: 413479 Open source
20232023-03-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -1787228 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -1.8M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-03-31	Operating cash flow	-768844	Operating Cash Flow: -768844 Open source
20192019-03-31	Operating cash flow	-711808	Operating Cash Flow: -711808 Open source
20202020-03-31	Operating cash flow	-554325	Operating Cash Flow: -554325 Open source
20212021-03-31	Operating cash flow	-986783	Operating Cash Flow: -986783 Open source
20222022-03-31	Operating cash flow	413479	Operating Cash Flow: 413479 Open source
20232023-03-31	Operating cash flow	-1787228	Operating Cash Flow: -1787228 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-03-31	Free cash flow	Unavailable	Operating Cash Flow: -768844 Open source
20192019-03-31	Free cash flow	Unavailable	Operating Cash Flow: -711808 Open source
20202020-03-31	Free cash flow	Unavailable	Operating Cash Flow: -554325 Open source
20212021-03-31	Free cash flow	Unavailable	Operating Cash Flow: -986783 Open source
20222022-03-31	Free cash flow	Unavailable	Operating Cash Flow: 413479 Open source
20232023-03-31	Free cash flow	Unavailable	Operating Cash Flow: -1787228 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

608.3% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Liabilities / assets	18.4%	Total Liabilities: 165999 Open source Total Assets: 899760 Open source
20192019-03-31	Liabilities / assets	466.7%	Total Liabilities: 613636 Open source Total Assets: 131472 Open source
20202020-03-31	Liabilities / assets	89,463.1%	Total Liabilities: 2878922 Open source Total Assets: 3218 Open source
20212021-03-31	Liabilities / assets	162.9%	Total Liabilities: 1223940 Open source Total Assets: 751435 Open source
20222022-03-31	Liabilities / assets	737%	Total Liabilities: 776890 Open source Total Assets: 105414 Open source
20232023-03-31	Liabilities / assets	608.3%	Total Liabilities: 1551139 Open source Total Assets: 255002 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.16× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Current assets / current liabilities	0.78×	Current Assets: 129806 Open source Current Liabilities: 165999 Open source
20192019-03-31	Current assets / current liabilities	0.21×	Current Assets: 131472 Open source Current Liabilities: 613636 Open source
20202020-03-31	Current assets / current liabilities	0×	Current Assets: 3218 Open source Current Liabilities: 2878922 Open source
20212021-03-31	Current assets / current liabilities	0.61×	Current Assets: 751435 Open source Current Liabilities: 1223940 Open source
20222022-03-31	Current assets / current liabilities	0.14×	Current Assets: 105414 Open source Current Liabilities: 776890 Open source
20232023-03-31	Current assets / current liabilities	0.16×	Current Assets: 255002 Open source Current Liabilities: 1551139 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2013-04-01 – 2014-03-31	−USD 1.92 million Exact value Exact value: -1917852 USD 2013-04-01 – 2014-03-31: -1917852 USD Inspect Net Income Open source Share or cite Citation for Net Income · Nascent Biotech Inc. · 2014-03-31 Nascent Biotech Inc. (edgar:1622057) Net Income: -1917852 USD Concept: fundies:NetIncome Period: 2013-04-01 to 2014-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3ANetIncome&period=2014-03-31&surface=latest&period_type=duration&start=2013-04-01&unit=USD&dimensions= Input fundies:NetIncome: -1917852 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793215004210/nbio-20150331.xml#27279 Filing: 000147793215004210 The citation records this snapshot. The page link may show a newer release later.	−USD 129,529 Exact value Exact value: -129529 USD 2013-04-01 – 2014-03-31: -129529 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nascent Biotech Inc. · 2014-03-31 Nascent Biotech Inc. (edgar:1622057) Operating Cash Flow: -129529 USD Concept: fundies:OperatingCashFlow Period: 2013-04-01 to 2014-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3AOperatingCashFlow&period=2014-03-31&surface=latest&period_type=duration&start=2013-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -129529 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793215004210/nbio-20150331.xml#31436 Filing: 000147793215004210 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2015 2014-04-01 – 2015-03-31	−USD 2.15 million Exact value Exact value: -2152129 USD 2014-04-01 – 2015-03-31: -2152129 USD Inspect Net Income Open source Share or cite Citation for Net Income · Nascent Biotech Inc. · 2015-03-31 Nascent Biotech Inc. (edgar:1622057) Net Income: -2152129 USD Concept: fundies:NetIncome Period: 2014-04-01 to 2015-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3ANetIncome&period=2015-03-31&surface=latest&period_type=duration&start=2014-04-01&unit=USD&dimensions= Input fundies:NetIncome: -2152129 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793216011373/nbio-20160331.xml#52996 Filing: 000147793216011373 The citation records this snapshot. The page link may show a newer release later.	−USD 473,297 Exact value Exact value: -473297 USD 2014-04-01 – 2015-03-31: -473297 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nascent Biotech Inc. · 2015-03-31 Nascent Biotech Inc. (edgar:1622057) Operating Cash Flow: -473297 USD Concept: fundies:OperatingCashFlow Period: 2014-04-01 to 2015-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3AOperatingCashFlow&period=2015-03-31&surface=latest&period_type=duration&start=2014-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -473297 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793216011373/nbio-20160331.xml#49859 Filing: 000147793216011373 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2015-04-01 – 2016-03-31	−USD 4.15 million Exact value Exact value: -4148740 USD 2015-04-01 – 2016-03-31: -4148740 USD Inspect Net Income Open source Share or cite Citation for Net Income · Nascent Biotech Inc. · 2016-03-31 Nascent Biotech Inc. (edgar:1622057) Net Income: -4148740 USD Concept: fundies:NetIncome Period: 2015-04-01 to 2016-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3ANetIncome&period=2016-03-31&surface=latest&period_type=duration&start=2015-04-01&unit=USD&dimensions= Input fundies:NetIncome: -4148740 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793217003089/nbio-20170331.xml#113022 Filing: 000147793217003089 The citation records this snapshot. The page link may show a newer release later.	−USD 170,421 Exact value Exact value: -170421 USD 2015-04-01 – 2016-03-31: -170421 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nascent Biotech Inc. · 2016-03-31 Nascent Biotech Inc. (edgar:1622057) Operating Cash Flow: -170421 USD Concept: fundies:OperatingCashFlow Period: 2015-04-01 to 2016-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3AOperatingCashFlow&period=2016-03-31&surface=latest&period_type=duration&start=2015-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -170421 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793217003089/nbio-20170331.xml#109745 Filing: 000147793217003089 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2016-04-01 – 2017-03-31	USD 1.14 million Exact value Exact value: 1136937 USD 2016-04-01 – 2017-03-31: 1136937 USD Inspect Net Income Open source Share or cite Citation for Net Income · Nascent Biotech Inc. · 2017-03-31 Nascent Biotech Inc. (edgar:1622057) Net Income: 1136937 USD Concept: fundies:NetIncome Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3ANetIncome&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:NetIncome: 1136937 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793218003263/nbio-20180331.xml#389272 Filing: 000147793218003263 The citation records this snapshot. The page link may show a newer release later.	−USD 768,844 Exact value Exact value: -768844 USD 2016-04-01 – 2017-03-31: -768844 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nascent Biotech Inc. · 2017-03-31 Nascent Biotech Inc. (edgar:1622057) Operating Cash Flow: -768844 USD Concept: fundies:OperatingCashFlow Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3AOperatingCashFlow&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -768844 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793218003263/nbio-20180331.xml#391397 Filing: 000147793218003263 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2017-04-01 – 2018-03-31	−USD 2.22 million Exact value Exact value: -2221299 USD 2017-04-01 – 2018-03-31: -2221299 USD Inspect Net Income Open source Share or cite Citation for Net Income · Nascent Biotech Inc. · 2018-03-31 Nascent Biotech Inc. (edgar:1622057) Net Income: -2221299 USD Concept: fundies:NetIncome Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3ANetIncome&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:NetIncome: -2221299 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793219005466/nbio-20190930.xml#84112 Filing: 000147793219005466 The citation records this snapshot. The page link may show a newer release later.	−USD 1.22 million Exact value Exact value: -1224381 USD 2017-04-01 – 2018-03-31: -1224381 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nascent Biotech Inc. · 2018-03-31 Nascent Biotech Inc. (edgar:1622057) Operating Cash Flow: -1224381 USD Concept: fundies:OperatingCashFlow Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3AOperatingCashFlow&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1224381 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793219005466/nbio-20190930.xml#103060 Filing: 000147793219005466 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2018-04-01 – 2019-03-31	−USD 1.37 million Exact value Exact value: -1368907 USD 2018-04-01 – 2019-03-31: -1368907 USD Inspect Net Income Open source Share or cite Citation for Net Income · Nascent Biotech Inc. · 2019-03-31 Nascent Biotech Inc. (edgar:1622057) Net Income: -1368907 USD Concept: fundies:NetIncome Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3ANetIncome&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:NetIncome: -1368907 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793220007399/nbio-20200930.xml#119162 Filing: 000147793220007399 The citation records this snapshot. The page link may show a newer release later.	−USD 711,808 Exact value Exact value: -711808 USD 2018-04-01 – 2019-03-31: -711808 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nascent Biotech Inc. · 2019-03-31 Nascent Biotech Inc. (edgar:1622057) Operating Cash Flow: -711808 USD Concept: fundies:OperatingCashFlow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3AOperatingCashFlow&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -711808 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793220007399/nbio-20200930.xml#172889 Filing: 000147793220007399 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2019-04-01 – 2020-03-31	−USD 4 million Exact value Exact value: -4004153 USD 2019-04-01 – 2020-03-31: -4004153 USD Inspect Net Income Open source Share or cite Citation for Net Income · Nascent Biotech Inc. · 2020-03-31 Nascent Biotech Inc. (edgar:1622057) Net Income: -4004153 USD Concept: fundies:NetIncome Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3ANetIncome&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:NetIncome: -4004153 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793221004504/nbio-20210331.xml#83641 Filing: 000147793221004504 The citation records this snapshot. The page link may show a newer release later.	−USD 554,325 Exact value Exact value: -554325 USD 2019-04-01 – 2020-03-31: -554325 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nascent Biotech Inc. · 2020-03-31 Nascent Biotech Inc. (edgar:1622057) Operating Cash Flow: -554325 USD Concept: fundies:OperatingCashFlow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3AOperatingCashFlow&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -554325 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793221004504/nbio-20210331.xml#113651 Filing: 000147793221004504 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2020-04-01 – 2021-03-31	−USD 958,767 Exact value Exact value: -958767 USD 2020-04-01 – 2021-03-31: -958767 USD Inspect Net Income Open source Share or cite Citation for Net Income · Nascent Biotech Inc. · 2021-03-31 Nascent Biotech Inc. (edgar:1622057) Net Income: -958767 USD Concept: fundies:NetIncome Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3ANetIncome&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:NetIncome: -958767 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793222007021/nbio_s1.htm#1298870 Filing: 000147793222007021 The citation records this snapshot. The page link may show a newer release later.	−USD 986,783 Exact value Exact value: -986783 USD 2020-04-01 – 2021-03-31: -986783 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nascent Biotech Inc. · 2021-03-31 Nascent Biotech Inc. (edgar:1622057) Operating Cash Flow: -986783 USD Concept: fundies:OperatingCashFlow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3AOperatingCashFlow&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -986783 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793222007021/nbio_s1.htm#1315382 Filing: 000147793222007021 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2021-04-01 – 2022-03-31	−USD 470,390 Exact value Exact value: -470390 USD 2021-04-01 – 2022-03-31: -470390 USD Inspect Net Income Open source Share or cite Citation for Net Income · Nascent Biotech Inc. · 2022-03-31 Nascent Biotech Inc. (edgar:1622057) Net Income: -470390 USD Concept: fundies:NetIncome Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3ANetIncome&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:NetIncome: -470390 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793224001231/nbio_s1.htm#943460 Filing: 000147793224001231 The citation records this snapshot. The page link may show a newer release later.	USD 413,479 Exact value Exact value: 413479 USD 2021-04-01 – 2022-03-31: 413479 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nascent Biotech Inc. · 2022-03-31 Nascent Biotech Inc. (edgar:1622057) Operating Cash Flow: 413479 USD Concept: fundies:OperatingCashFlow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3AOperatingCashFlow&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 413479 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793224001231/nbio_s1.htm#963161 Filing: 000147793224001231 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2022-04-01 – 2023-03-31	−USD 2.8 million Exact value Exact value: -2800969 USD 2022-04-01 – 2023-03-31: -2800969 USD Inspect Net Income Open source Share or cite Citation for Net Income · Nascent Biotech Inc. · 2023-03-31 Nascent Biotech Inc. (edgar:1622057) Net Income: -2800969 USD Concept: fundies:NetIncome Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3ANetIncome&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=USD&dimensions= Input fundies:NetIncome: -2800969 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793224004020/nbio_10k.htm#540905 Filing: 000147793224004020 The citation records this snapshot. The page link may show a newer release later.	−USD 1.79 million Exact value Exact value: -1787228 USD 2022-04-01 – 2023-03-31: -1787228 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Nascent Biotech Inc. · 2023-03-31 Nascent Biotech Inc. (edgar:1622057) Operating Cash Flow: -1787228 USD Concept: fundies:OperatingCashFlow Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T17:58:29Z Snapshot: df5935d77e3e3477490677e5af95a922768ab22a96751305371fb10884b49b1c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1622057/explain?concept=fundies%3AOperatingCashFlow&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1787228 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1622057/000147793224004020/nbio_10k.htm#609453 Filing: 000147793224004020 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

52 filings · 1,714 latest values · 1,714 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001622057, 1622057, edgar:1622057

Also known as NASCENT BIOTECH INC, NASCENT BIOTECH INC., Nascent Biotech Inc.

Nascent Biotech Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2023 2022-04-01 – 2023-03-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation